Mr Garnier said the company had absorbed over Â£1.5bn of lost sales to generics but still managing to grow the business.Chief executive Jean-Pierre Garnier said it had been a "difficult year"."2005 will also be an important year in terms of research and development pipeline progress."However, the firm discontinued development of an experimental treatment for obesity, known as '771, after disappointing clinical trial results.